Advertisement

Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x100px
Document › Details

Teneobio, Inc.. (6/8/20). "Press Release: Teneobio Enters a Research Collaboration and Licensing Agreement to Develop Next Generation Engineered Cell Therapies with Intellia Therapeutics". Newark, CA.

Organisations Organisation Teneobio Inc.
  Organisation 2 Intellia Therapeutics Inc. (Nasdaq: NTLA)
Products Product UniAbs™ (Human Heavy Chain Antibodies )
  Product 2 T cell therapy
Persons Person Vafa, Omid (TeneoBio 201706 CBO)
  Person 2 Schiermeier, Andrew (Intellia Therapeutics 202106 EVP + COO before Merck (DE) 201504 Head Global Oncology)
     


Teneobio, Inc. announced that it has entered into a research collaboration and licensing agreement with Intellia Therapeutics, a CRISPR/Cas9 therapeutics company, to use Teneobio’s Heavy Chain Antibodies (UniAbs®) for Intellia’s next generation engineered cell therapies. In addition, Teneobio will use its proprietary platforms to discover novel UniAbs® against targets which can be used in engineered cell therapies for various life-threatening diseases. Intellia will have the option to exclusively license the novel antibodies for global development and commercialization.

Under the terms of the agreement, Teneobio will receive an upfront payment and will be eligible to receive additional payments based on achievement of certain clinical and regulatory milestones, as well as royalties on future potential sales.

Omid Vafa, Chief Business Officer at Teneobio, said, “We are excited to partner with Intellia, a pioneer of genome editing treatments. Together we aim to create the next generation of engineered cell therapies. Teneobio’s unique discovery platform rapidly identifies UniAbs with excellent developability profiles, enabling the engineering of modular multispecifics. These advantages will be valuable in creating next generation differentiated cellular therapies.”

Andrew Schiermeier, Chief Operating Officer at Intellia, added, “We believe that the combined power of Teneobio’s antibody discovery platform and Intellia’s proprietary approaches to T-cell engineering will accelerate the development of genome editing products for patients.”


About Teneobio, Inc.

Teneobio, Inc. is a clinical stage biotechnology company developing a new class of biologics, Human Heavy-Chain Antibodies (UniAb®), for the treatments of cancer, autoimmunity, and infectious diseases. Teneobio’s discovery platform, TeneoSeek, comprises genetically engineered animals (UniRat® and OmniFlic®), next-generation sequencing, bioinformatics and high-throughput vector assembly technologies. TeneoSeek rapidly identifies large numbers of unique binding molecules specific for therapeutic targets of interest. Versatile antibody variable domains (UniDab®) derived from UniAb® can be assembled into multi-specific and multivalent therapeutic proteins, surpassing limitations of conventional antibody therapeutics. Teneobio’s “plug-and-play” T-cell engaging platform includes a diverse set of anti-CD3 antibodies for therapeutics with optimal efficacy and reduced toxicity.

Teneobio partners include AbbVie, Janssen, GSK, Kite and Poseida. For more information, please visit www.teneobio.com.


Company Inquiries for Teneobio, Inc.

Omid Vafa, Chief Business Officer
ovafa@teneobio.com

   
Record changed: 2023-06-05

Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Teneobio Inc.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x300px




» top